MAZE

Maze Therapeutics, Inc.
CAPPED RATING

Maze Therapeutics, Inc. (MAZE) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D-). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C
Factor Score 2.4 / 5.0
Growth
D-
Factor Score 0.9 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -11.2
EV / EBITDA -10.1
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M 32.8%
Price Return 12M 11.9%
Catalyst Signal 0.00
Market Cap $2.0B
TTM Revenue $20.0M
Price / Sales 98.7
ROE -37.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C (2.4) D- (0.9) B- (3.0) B (3.2) C+ (2.6) C (2.4)
2026-11-06 C (2.5) D- (0.8) B- (3.0) B- (3.1) C+ (2.7) C (2.4)
2026-10-30 C (2.5) D- (0.8) B- (3.0) B- (3.0) C+ (2.7) C (2.4)
2026-10-23 C (2.5) D- (0.8) B- (3.0) B- (3.0) C+ (2.6) C (2.4)
2026-10-16 C+ (2.5) D- (0.8) B- (3.0) C (2.4) C+ (2.6) C (2.3)
Page 1 of 4